BioCryst Pharmaceuticals BCRX Interest Expense
Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's interest expense?
- BioCryst Pharmaceuticals (BCRX) reported interest expense of $19.78M in Q1 2026.
- How has BioCryst Pharmaceuticals's interest expense changed year-over-year?
- BioCryst Pharmaceuticals's interest expense decreased by 15.8% year-over-year, from $23.49M to $19.78M.
- What is the long-term trend for BioCryst Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's interest expense has grown at a 7.4% compound annual growth rate (CAGR), from $59.29M to $78.87M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.